
Heart rate recovery, cardiac rehabilitation, and erectile dysfunction in males with ischemic heart disease

To the Editor,

I have read the article entitled "Heart rate recovery, cardiac rehabilitation, and erectile dysfunction in males with ischemic heart disease" by Kałka et al. (1) with great interest, which was recently published in *Anatolian Journal of Cardiology* 2016; 16: 256-63. The investigators reported that in patients with ischemic heart disease (IHD) and erectile dysfunction (ED) subjected to cardiac rehabilitation, enhancement of autonomic balance assessed using heart rate recovery (HRR) plays a significant role in the mechanism of improvement in erection quality (1). Authors have reported that there was no significant difference with regard to beta-blocker therapy (1).

Beta-blockers are one of the most commonly used and cornerstone therapy in the treatment of ischemic heart disease (2). Nebivolol is a third-generation beta-blocker, and has a vasodilating effect that is attributed to the generation of endothelial nitric oxide, in addition to β_1 -adrenoceptor selectivity (3).

It is well known that beta-blocker therapy effect might be different with regard to ED depending on sort of it in patients with IHD (4). Aldemir et al. (4) have reported that although ED in males undergoing CABG surgery decreases when metoprolol is used, nebivolol had a protective effect on the sexual activity of men undergoing coronary artery bypass surgery with cardiopulmonary bypass. In addition, Brixius et al. (5) have reported beneficial effects of nebivolol on the erectile function in hypertensive men.

I would like to emphasize one important point to clarify in this article. Kind of beta-blocker therapy is very important to evaluate ED in patients with IHD (3–5). Therefore, authors should mention kind of beta-blocker therapy used in this study group.

In conclusion, ED is more common in men with IHD. Nebivolol, a third-generation beta-blocker, seems to have beneficial effects on ED compared with metoprolol (3–5). Kind of beta-blocker therapy might affect ED in patients with IHD.

Levent Cerit**Department of Cardiology, Near East University; Nicosia-Turkish Republic of Northern Cyprus****References**

1. Kałka D, Domagała Z, Rusiecki L, Karpiński Ł, Gebala J, Kołęda P, et al. Heart rate recovery, cardiac rehabilitation and erectile dysfunction in males with ischaemic heart disease. *Anatol J Cardiol* 2016; 16: 256-63
2. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). *J Am Coll Cardiol* 1999; 34: 890-911.
3. Van de Water A, Janssens W, Van Neuten J, Xhonneux R, De Cree J, Verhaegen H, et al. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. *J Cardiovasc Pharmacol* 1988; 11: 552-63.
4. Aldemir M, Keleş İ, Karalar M, Tecer E, Adalı F, Pektaş MB, et al. Nebivolol compared with metoprolol for erectile function in males undergoing coronary artery bypass graft. *Anatol J Cardiol* 2016; 16: 131-6.
5. Brixius K, Middeke M, Lichtenthal A, Jahn E, Schwinger RH. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. *Clin Exp Pharmacol Physiol* 2007; 34: 327-31.

Address for Correspondence: Dr. Levent Cerit

Near East Hospital University Hospital

Nicosia-Turkish Republic of Northern Cyprus

Phone: +90 392 675 10 00 E-mail: drcerit@hotmail.com

©Copyright 2016 by Turkish Society of Cardiology - Available online at www.anatoljcardiol.com

DOI:10.14744/AnatolJCardiol.2016.7229

